[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY34657A - ?derivados macrocíclicos para el tratamiento de enfermedades?. - Google Patents

?derivados macrocíclicos para el tratamiento de enfermedades?.

Info

Publication number
UY34657A
UY34657A UY34657A UY34657A UY34657A UY 34657 A UY34657 A UY 34657A UY 34657 A UY34657 A UY 34657A UY 34657 A UY34657 A UY 34657A UY 34657 A UY34657 A UY 34657A
Authority
UY
Uruguay
Prior art keywords
diseases
treatment
macrocyclic derivatives
macrocyclic
derivatives
Prior art date
Application number
UY34657A
Other languages
English (en)
Inventor
Kath John Charles
Bailey Simon
Burke Benjamin Joseph
Collins Michael Raymond
Cui Jingrong Jean
Deal Judith Gail
Hoffman Robert Louis
Huang Qinhua
Johnson Ted William
Kania Robert Steven
Le Phuong Thi Quy
Mctigue Michele Ann
Palmer Cynthia Louise
Richardson Paul Francis
Sach Neal William
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48142828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34657(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of UY34657A publication Critical patent/UY34657A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos de la fórmula (F )como se define además en la presente y a sus sales farmacéuticamente aceptables, a composiciones farmacéuticas que comprenden dichos compuestos y sales, y a sus usos. Los compuestos y las sales de la presente invención inhiben la quinasa del linfoma anaplásico (ALK) y/o EML4-ALK y son útiles para tratar o mejorar los trastornos proliferativos celulares anormales, tales como cáncer.
UY34657A 2012-03-06 2013-03-06 ?derivados macrocíclicos para el tratamiento de enfermedades?. UY34657A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607485P 2012-03-06 2012-03-06
US201361759307P 2013-01-31 2013-01-31

Publications (1)

Publication Number Publication Date
UY34657A true UY34657A (es) 2013-10-31

Family

ID=48142828

Family Applications (1)

Application Number Title Priority Date Filing Date
UY34657A UY34657A (es) 2012-03-06 2013-03-06 ?derivados macrocíclicos para el tratamiento de enfermedades?.

Country Status (46)

Country Link
US (2) US8680111B2 (es)
EP (1) EP2822953B9 (es)
JP (2) JP5823066B2 (es)
KR (1) KR101692600B1 (es)
CN (1) CN104169286B (es)
AP (1) AP2014007881A0 (es)
AR (1) AR090230A1 (es)
AU (1) AU2013229173B2 (es)
BR (1) BR112014022106B1 (es)
CA (1) CA2863892C (es)
CL (1) CL2014002084A1 (es)
CO (1) CO7061081A2 (es)
CR (1) CR20140370A (es)
CY (2) CY1118771T1 (es)
DK (1) DK2822953T5 (es)
DO (1) DOP2014000188A (es)
EA (1) EA026155B9 (es)
ES (1) ES2621220T3 (es)
FR (1) FR19C1062I2 (es)
GE (1) GEP201606560B (es)
GT (1) GT201400187A (es)
HK (1) HK1199247A1 (es)
HR (1) HRP20170287T2 (es)
HU (2) HUE034118T2 (es)
IL (1) IL234062A (es)
LT (2) LT2822953T (es)
LU (1) LUC00131I2 (es)
MD (1) MD4590C1 (es)
ME (1) ME02630B (es)
MX (1) MX350844B (es)
MY (1) MY169142A (es)
NI (1) NI201400102A (es)
NL (1) NL301006I2 (es)
NO (1) NO2019034I1 (es)
NZ (1) NZ627900A (es)
PE (1) PE20142339A1 (es)
PH (1) PH12014501992A1 (es)
PL (1) PL2822953T3 (es)
PT (1) PT2822953T (es)
RS (1) RS55814B1 (es)
SG (1) SG11201404451TA (es)
SI (1) SI2822953T1 (es)
TW (1) TWI476199B (es)
UY (1) UY34657A (es)
WO (1) WO2013132376A1 (es)
ZA (1) ZA201406244B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105026373B (zh) 2013-01-31 2018-03-30 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
ES2656189T3 (es) 2013-06-28 2018-02-26 Pfizer Inc. Formas sólidas de un inhibidor macrocíclico de quinasa
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
RS57700B1 (sr) 2013-12-13 2018-12-31 Vertex Pharma Prolekovi piridonskih amida korisni kao modulatori kanala za natrijum
KR102402179B1 (ko) 2014-01-24 2022-05-25 터닝 포인트 테라퓨틱스, 인크. 단백질 키나제의 조절인자로서의 다이아릴 거대환
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ros1突變癌細胞之分子
CN103772272A (zh) * 2014-03-04 2014-05-07 定陶县友帮化工有限公司 2-boc-氨基-3-羟基-5-溴吡啶的合成方法
EP3183256A4 (en) * 2014-08-20 2018-05-30 Teligene Ltd. Substituted macrocycles useful as kinases inhibitors and methods of use thereof
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
US9663535B2 (en) * 2014-10-13 2017-05-30 Atrin Pharmaceuticals LLC Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
MX2017009246A (es) * 2015-01-16 2017-10-12 Chugai Pharmaceutical Co Ltd Farmaco de combinacion.
MX2017017097A (es) 2015-07-02 2018-05-23 Tp Therapeutics Inc Macrociclos diarílicos quirales como moduladores de proteínas quinasas.
PL3319969T3 (pl) 2015-07-06 2024-06-24 Turning Point Therapeutics, Inc. Diarylowe polimorfy makrocykliczne
MX2018000718A (es) 2015-07-21 2020-01-20 Turning Point Therapeutics Inc Macrociclos de diarilo quirales y usos de los mismos.
SI3798222T1 (sl) 2015-07-31 2024-02-29 Pfizer Inc. Kristalna oblika proste baze lorlatiniba
EP3355902B1 (en) 2015-09-30 2022-04-13 Merck Patent GmbH Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
CN112920201A (zh) * 2016-03-03 2021-06-08 深圳市塔吉瑞生物医药有限公司 一种大环化合物及包含该化合物的组合物
CN105732355A (zh) * 2016-04-07 2016-07-06 戊言医药科技(上海)有限公司 1-(5-氟-2-碘苯基)乙酮的制备方法
CN105646355A (zh) * 2016-04-07 2016-06-08 戊言医药科技(上海)有限公司 3-(羟甲基)-1-甲基-吡唑-5-甲腈的制备方法
WO2017175091A1 (en) 2016-04-08 2017-10-12 Pfizer Inc. Crystalline forms of lorlatinib maleate
US10301324B2 (en) 2016-04-12 2019-05-28 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use
CN105801603B (zh) * 2016-04-13 2018-10-02 成都倍特药业有限公司 一种具有大环结构的alk抑制剂及其制备方法
CA3031100A1 (en) 2016-07-28 2018-02-01 Tp Therapeutics, Inc. Macrocycle kinase inhibitors
CN110023313B (zh) * 2016-12-02 2022-10-25 豪夫迈·罗氏有限公司 二环酰胺化合物及其使用方法
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018137679A1 (en) * 2017-01-25 2018-08-02 Teligene Ltd Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile
MX2019013574A (es) 2017-05-16 2019-12-18 Vertex Pharma Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.
PL3615527T3 (pl) 2017-06-30 2024-07-01 Elanco Animal Health Gmbh Nowe pochodne azachinoliny
CN110913842A (zh) 2017-07-19 2020-03-24 伊尼塔公司 包括恩曲替尼的药物组合物
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
RU2020113141A (ru) 2017-10-10 2021-11-12 Пфайзер Инк. Кристаллическая форма гидрата свободного основания лорлатиниба
EP3697390A1 (en) 2017-10-17 2020-08-26 Ignyta, Inc. Pharmaceutical compositions and dosage forms
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
JOP20200152A1 (ar) 2017-12-19 2022-10-30 Turning Point Therapeutics Inc مركبات حلقية كبرى لعلاج مرض
JP2021512935A (ja) 2018-02-12 2021-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 疼痛を処置する方法
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
EP3784675A1 (en) 2018-04-23 2021-03-03 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
WO2019210835A1 (zh) * 2018-05-04 2019-11-07 正大天晴药业集团股份有限公司 作为蛋白激酶调节剂的二芳基大环化合物
CN108621206B (zh) * 2018-05-07 2020-08-14 昆山国显光电有限公司 手套箱系统以及手套箱系统的保养方法
KR20210063332A (ko) * 2018-09-18 2021-06-01 가부시키가이샤 야쿠르트 혼샤 퀴놀린카르복사미드 유도체를 사용하는 암 병용 요법
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
CN109081810A (zh) * 2018-09-20 2018-12-25 沈阳药科大学 1-甲基-3–((甲氨基)甲基)-1h-吡唑-5-腈的合成方法
WO2020108522A1 (zh) * 2018-11-28 2020-06-04 深圳市塔吉瑞生物医药有限公司 一种氘代大环化合物的制备方法
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CN109651418A (zh) * 2019-01-25 2019-04-19 安庆多辉生物科技有限公司 一种劳拉替尼原料药合成中间体及有机金属钯催化偶联制备劳拉替尼的方法
CN109651397A (zh) * 2019-01-25 2019-04-19 安庆多辉生物科技有限公司 一种劳拉替尼中间体及制备劳拉替尼的方法
CN109651398B (zh) * 2019-01-25 2021-07-30 安庆多辉生物科技有限公司 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法
CN111499514B (zh) * 2019-01-31 2024-09-20 连云港润众制药有限公司 一种罗沙司他中间体的制备方法
EP3941457A4 (en) 2019-03-21 2023-04-26 Merck Sharp & Dohme LLC HISTONE-DEACETYLASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF HIV INFECTION
KR20220004206A (ko) * 2019-05-14 2022-01-11 텔리진 엘티디. 키네이스 억제제로 유용한 치환된 거대고리화합물
US20220289764A1 (en) * 2019-07-18 2022-09-15 Pliva Hrvatska D.O.O. Crystalline lorlatinib : fumaric acid and solid state form thereof
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
CN110483551B (zh) * 2019-08-30 2021-10-22 北京赛思源生物医药技术有限公司 一种劳拉替尼游离碱的晶体
WO2021069571A1 (en) 2019-10-10 2021-04-15 Sandoz Ag Polymorph of lorlatinib
CN112812128B (zh) * 2019-11-18 2024-04-02 正大天晴药业集团股份有限公司 作为alk和ros调节剂的大环化合物
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
CA3164134A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
CN111170908B (zh) * 2020-01-09 2021-08-17 北京印刷学院 一种2,4-二甲基-3-甲磺酰基卤苯的合成方法
US20230117684A1 (en) 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
KR20240131463A (ko) 2020-05-05 2024-08-30 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
KR102699528B1 (ko) * 2020-05-05 2024-08-30 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
WO2021233296A1 (zh) * 2020-05-18 2021-11-25 深圳市塔吉瑞生物医药有限公司 大环化合物的固体形式及其制备和用途
IL299732A (en) * 2020-07-10 2023-03-01 Blossomhill Therapeutics Inc Macrocycles and their use
IL303419A (en) * 2020-12-17 2023-08-01 Blossomhill Therapeutics Inc Macrocyclic compounds and their use
CN114805371B (zh) * 2021-01-19 2024-05-24 江苏开元药业有限公司 含2-氨基嘧啶大环类化合物及其制备方法和用途
WO2022182845A1 (en) * 2021-02-25 2022-09-01 Blossomhill Therapeutics, Inc. Macrocycles and their use
EP4320153A1 (en) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
CN115246843A (zh) * 2021-04-26 2022-10-28 苏州东南药业股份有限公司 一类十四元稠环衍生物及其应用
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
EP4408844A1 (en) * 2021-10-01 2024-08-07 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
EP4230201A1 (en) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Composition for treating neurodegenerative diseases
WO2023156983A1 (en) 2022-02-21 2023-08-24 Universidade Nova De Lisboa Compounds and compositions for neurodegenerative diseases
WO2024086634A1 (en) * 2022-10-19 2024-04-25 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
CN115746023B (zh) * 2022-10-27 2024-08-09 复旦大学 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法
CN118434744A (zh) * 2022-12-01 2024-08-02 中国医药研究开发中心有限公司 含氮大环类化合物及其制备方法和医药用途
WO2024146541A1 (en) * 2023-01-03 2024-07-11 Guangdong Newopp Biopharmaceuticals Co., Ltd. Macrocyclic compounds as usp1 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
RS53118B (en) 2003-02-26 2014-06-30 Sugen Inc. AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
US7456170B2 (en) 2004-08-25 2008-11-25 Pfizer Inc. Triazolobenzodiazepines and their use as vasopressin antagonists
AU2005276135B2 (en) 2004-08-26 2011-04-28 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
CA2577937C (en) 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
SI1963302T1 (sl) 2005-12-05 2013-04-30 Pfizer Products Inc. Polimorfne oblike inhibitorja c-met/hgfr
ATE488237T1 (de) 2005-12-05 2010-12-15 Pfizer Prod Inc Verfahren zur behandlung von abnormalem zellwachstum
CA2675755C (en) 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
US8362236B2 (en) 2007-03-01 2013-01-29 Chugai Seiyaku Kabushiki Kaisha Macrocyclic compound
EP2125851B1 (en) * 2007-03-13 2010-06-23 Pfizer Products Inc. Erythromycin-based macrolides
JP2011511005A (ja) * 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 2−アミノピリジン系キナーゼ阻害薬
WO2009132202A2 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
JP5531011B2 (ja) * 2008-06-06 2014-06-25 サノフイ TAFIaの阻害剤としての大環状尿素およびスルファミド誘導体
AU2009288021B2 (en) * 2008-09-08 2015-06-18 Merck Patent Gmbh Macrocyclics pyrimidines as Aurora kinase inhibitors
US8765727B2 (en) * 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
JP2013508323A (ja) 2009-10-21 2013-03-07 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 合成大環状アミドhdac6阻害剤化合物およびそれらの治療剤としての用途
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
JP2013525476A (ja) * 2010-05-04 2013-06-20 ファイザー・インク Alk阻害剤としての複素環式誘導体
PL3205654T3 (pl) * 2010-05-20 2019-08-30 Array Biopharma, Inc. Związki makrocykliczne jako inhibitory kinazy TRK
US8975232B2 (en) 2010-07-29 2015-03-10 President And Fellows Of Harvard College Macrocyclic kinase inhibitors and uses thereof
WO2012125603A1 (en) 2011-03-16 2012-09-20 Cephalon, Inc. Macrocyclic compounds as alk, fak and jak2 inhibitors

Also Published As

Publication number Publication date
DK2822953T3 (en) 2017-04-03
NL301006I2 (nl) 2020-04-14
HRP20170287T1 (hr) 2017-04-21
ES2621220T9 (es) 2017-11-23
CR20140370A (es) 2014-08-21
CO7061081A2 (es) 2014-09-19
TW201350484A (zh) 2013-12-16
EA026155B1 (ru) 2017-03-31
FR19C1062I1 (es) 2019-11-22
JP6002825B2 (ja) 2016-10-05
US9133215B2 (en) 2015-09-15
HUS1900040I1 (hu) 2019-09-30
DK2822953T5 (en) 2017-09-11
WO2013132376A1 (en) 2013-09-12
DOP2014000188A (es) 2014-11-16
AU2013229173A1 (en) 2014-08-21
ZA201406244B (en) 2015-05-27
KR20140137414A (ko) 2014-12-02
MD20140086A2 (ro) 2015-01-31
LTPA2019519I1 (lt) 2019-11-11
NO2019034I1 (no) 2019-08-19
KR101692600B1 (ko) 2017-01-03
MX2014010716A (es) 2014-09-22
RS55814B1 (sr) 2017-08-31
US20130252961A1 (en) 2013-09-26
LTC2822953I2 (lt) 2020-12-28
NZ627900A (en) 2016-08-26
ES2621220T3 (es) 2017-07-03
IL234062A (en) 2017-08-31
CY2019033I2 (el) 2019-11-27
LT2822953T (lt) 2017-04-10
CN104169286A (zh) 2014-11-26
EP2822953B9 (en) 2017-06-21
JP2015510879A (ja) 2015-04-13
BR112014022106B1 (pt) 2022-08-02
CL2014002084A1 (es) 2014-11-03
US20140135339A1 (en) 2014-05-15
AU2013229173B2 (en) 2017-06-01
MD4590B1 (ro) 2018-08-31
MD4590C1 (ro) 2019-03-31
CY1118771T1 (el) 2017-07-12
NI201400102A (es) 2015-03-05
AR090230A1 (es) 2014-10-29
AP2014007881A0 (en) 2014-08-31
BR112014022106A2 (pt) 2017-07-11
JP2016041709A (ja) 2016-03-31
GEP201606560B (en) 2016-10-25
LUC00131I1 (es) 2019-10-11
EA026155B9 (ru) 2017-06-30
MX350844B (es) 2017-09-22
FR19C1062I2 (fr) 2020-09-04
GT201400187A (es) 2015-10-15
LUC00131I2 (es) 2020-07-16
CY2019033I1 (el) 2019-11-27
EA201491394A1 (ru) 2015-05-29
CA2863892A1 (en) 2013-09-12
ME02630B (me) 2017-06-20
EP2822953A1 (en) 2015-01-14
CN104169286B (zh) 2016-06-08
SG11201404451TA (en) 2014-09-26
SI2822953T1 (sl) 2017-04-26
PH12014501992B1 (en) 2014-11-24
PT2822953T (pt) 2017-04-06
HRP20170287T2 (hr) 2017-11-03
TWI476199B (zh) 2015-03-11
JP5823066B2 (ja) 2015-11-25
PH12014501992A1 (en) 2014-11-24
EP2822953B1 (en) 2017-02-01
HK1199247A1 (zh) 2015-06-26
CA2863892C (en) 2016-08-30
PE20142339A1 (es) 2015-01-15
HUE034118T2 (en) 2018-01-29
MY169142A (en) 2019-02-18
PL2822953T3 (pl) 2017-07-31
US8680111B2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CO2017004736A2 (es) Péptidos macrociclicos útiles como inmunomoduladores
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34648A (es) Amidas como inhibidores de pim
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
UY34820A (es) Compuestos tipo pirrolo-pirrolidinona
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34591A (es) Compuestos de imidazopirrolidinona
UY36311A (es) Indazoles sustituidos con bencilo
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY34778A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?.
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20220527